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Abstract
Background: Hepatocellular carcinoma (HCC) is a molecular complex tumor with high intrinsic drug resistance.
Recent evidence suggests an involvement of the tyrosine kinase pathway in the regulation of ATP-binding cassette
protein (ABC-transport protein) mediated multidrug resistance in cancer cells. The aim of this study was to examine
whether EGFR inhibition sensitizes HCCs to chemotherapy and to elucidate its mechanism.
Results: Chemotherapeutic treatment induces multidrug resistance and significantly increases ABC-transport protein
expression and function in a time- and dose-dependent manner in HCC cells. Furthermore, cytostatic treatment
increases the mRNA expression of tyrosine kinases and induces the phosphorylation of ERK. EGF activation of the
tyrosine kinase pathway up-regulated the ABC-transport protein mRNA expression and enhanced the survival of
resistant HCC cells. Consistent with these effects, inhibition of the EGFR using siRNA decreased the ABC-transport
protein mRNA expression and inhibited the proliferation of resistant cells. Additional treatment with Gefitinib, a clinically
approved EGFR inhibitor, caused a dose-dependent reversal of resistance to conventional chemotherapy.
Conclusion: The present study demonstrates that the multidrug resistance of HCC is modulated through the EGF-
activated tyrosine kinase cascade. Consequentially, the restoration of chemosensitivity by EGFR inhibition may lead
towards new tailored therapies in patients with highly resistant tumors.
Background
Hepatocellular carcinoma (HCC) is a major health pro-
blem worldwide. Its incidence is increasing continuously
in the Western world. In the United States and Europe the
diagnosis of HCC has almost doubled during the last two
decades [1]. Despite recent improvements in surveillance
programs and diagnostic tools, only 30-40% of HCC
patients are eligible for liver resection or transplantation,
the only curative treatment options to date [2]. The tyro-
sine kinase inhibitor sorafenib is the current standard of
care for palliative treatment; the partial response rate,
however, is only about 10% [3]. Conventional systemic
chemotherapy has shown only minor effectiveness with
response rates far below 10% [4]. A substantial resistance
against structurally and functionally unrelated cytostatic
drugs develops through the destruction of vulnerable and
negative chemoresistant tumor cell populations during
hepatocarcinogenesis. An increased cellular extrusion of
chemotherapeutics by multidrug resistance mediating
ABC-transport proteins (MDR proteins) and consequently
reduced cytostatic activity has been described [5]. The
expression of transmembrane ABC-transport proteins in
HCC has been demonstrated in vitro and in vivo [6,7].
However, the over-expression of MDR proteins is an inde-
pendent prognostic factor, associated with increased vas-
cular and lymphatic invasion, shorter disease-free survival
as well as significantly reduced overall survival [8-10].
An association of the tyrosine kinase pathway with the
development and regulation of multidrug resistance
(MDR) has been discussed in various tumor entities
[11-14]. The epidermal growth factor receptor (EGFR)-
associated activation of the tyrosine kinase pathway plays
a key role in the signal transduction of cell differentiation,
motility and proliferation in HCC. Guan et al. have
demonstrated an increased tyrosine kinase activity in resis-
tant hepatoma cells [15]. The induction of the tyrosine
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sequentially increased MDR gene expression has been dis-
cussed previously in breast cancer cells [16]. However, the
involvement of the EGFR in the development of MDR in
HCC has not yet been elucidated.
We show for the first time that conventional cytostatics
induce the EGF-activated tyrosine kinase pathway leading
to the induction of ATP-binding cassette protein mediated
multidrug resistance in HCC. Moreover, we present the
evidence that EGFR inhibition is a potent sensitizer for
chemotherapeutic treatment in cancer cells.
Material and methods
HCC cell line
The human HCC cell line HepG2 (Toni Lindl GmbH,
Munich, Germany) was used for in vitro experiments,
cultured in RPMI 1640/DMEM containing 10% fetal
bovine serum (FBS) in 5% CO2 at 37°C [17]. Cell culture
reagents were obtained from Life Technologies Inc.
(Gaithersburg, USA), unless indicated otherwise.
Chemotherapeutic treatment
Gemcitabine (Lilly, Indianapolis, USA) and doxorubicin
(Sandoz Pharmaceuticals GmbH, Holzkirchen, Ger-
many) were prepared according to the manufacturer’s
instructions in the Pharmacy of the university hospital
of Heidelberg. Gefitinib (AstraZeneca, London, UK)
were prepared according to the manufacturer’si n s t r u c -
tion by dissolving in DMSO. Cells were treated as fol-
lows for induction of drug resistance: untreated
controls, twice weekly, gemcitabine or doxorubicin at
two different concentrations (11.4 μg/ml and 114 μg/ml
or 0.15 μg/ml and 1.5 μg/ml, respectively). EGF effects
were assessed in the following groups: untreated con-
trols, EGF 500 ng/ml (Biomol, Hamburg, Germany) for
24 hours, gemcitabine in the above-mentioned doses
either in combination with EGF or alone. Effects of gefi-
tinib were analysed in the following groups: untreated
controls, gefitinib 10 μg/ml, gemcitabine or doxorubicin
in the above-mentioned doses in combination with gefi-
tinib or alone.
MTT assay
Cells at 2 × 10
3 were seeded into 96-well plates and cul-
tured in 100 μl medium. Cells were treated as men-
tioned above, and 24, 48, 72 and 96 hours after
treatment, MTT [3-(4, 4- dimeththiazol-2-yl)2, 5-diphe-
nylterazolium bromide] in PBS was added to each well,
incubated for 4 hours at 37°C and dissolved in 100 μlo f
propanol-2. The absorbance was recorded at 570 nm on
a photometer (Eppendorf, Germany). A minimum of
four independent experiments were performed in each
treatment group.
RT-PCR
T o t a lR N Aw a si s o l a t e df r o mc e l l sa n dt r a n s c r i p t e dt o
cDNA according to the manufacturers’ instructions
(RNeasy Mini Kit, Qiagen, Hilden, Germany; Transcriptor
First Strand cDNA Synthesis Kit, Roche Diagnostics,
Basel, Switzerland). Semi-quantitative RT-PCR analysis
was performed using Power SYBR Green as fluorescent
probe and the StepOne RT-PCR System (Applied Biosys-
tem, Foster City, USA). The human GAPDH was used as
endogenous control. Commercially available primers for
GAPDH, MRP1, MRP2, MRP3, PGP and EGFR were used
(Qiagen, Hilden, Germany). Primers for RAF1 (Genbank
NM002880), MEK (Genbank NM002755), ERK (Genbank
NM002745) and MAPK14 (Genbank NM001315) were
designed using NCBI Primer-Blast software and produced
by Invitrogen, Carlsbad, USA. (Table 1) In brief, after 10
minutes of denaturation at 95°C, RT-PCR was carried out
for 40 cycles at 95°C for 15 s and extension at 60°C for
60 s. The fluorescent signal was measured at the end of
the annealing phase of each cycle. mRNA quantification
was recorded and analyzed with the 2(-Delta Delta C(T))
method using the StepOne RT-PCR System (Applied Bio-
system) [18]. All samples were measured in triplicates.
Two wells were used to monitor contamination in every
run. The efficiency of primers was evaluated by serial dilu-
tion of cDNA and an efficiency of ≥ 85% was reached.
Western blot
HepG2 cells were lysed and 40 μg of total protein was
separated by electrophoresis on a SDS-PAGE and trans-
ferred to PVDF membranes using an XCell IITM Blot
Module (Invitrogen, Carlsbad, USA). Blotting was per-
formed with PBS containing 0.05% Tween 20 plus 5%
BSA and incubated overnight with primary antibodies
(PGP, MRP1, MRP2, MRP3, ERK all Santa Cruz Biotech-
n o l o g yI n c . ,S a n t aC r u z ,U S A ,E G F Ra n dp E R KC e l ls i g -
nalling Technology, Danvers, MA, USA, Actin Sigma
Aldrich, Munich, Germany) at 4°C. The horseradish-per-
oxidase conjugated secondary antibody (Santa Cruz) was
used for protein detection at room temperature for 2
hours, followed by chemiluminescence detection (ECL
Western blot Analysis System, GE Healthcare, Munich,
Germany). The results of Western blot were analyzed
with the analysis software QUANTITY ONE (BIO-RAD
Laboratories, Hercules, CA, USA).
EGFR inhibition
EGFR small interfering RNA (siRNA) duplexes that tar-
get the sequences 5’-TACGAATATTAAACACTTCAA-
3’ and high-purity positive control siRNA oligo-nucleo-
tides were used for siRNA experiments following the
manufacturer’s instructions (Qiagen, Hilden, Germany).
Cells at 4 × 10
4 were seeded in the 6-well plates and
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12 μl transfection reagent according to the manufac-
turer’s protocol (HiPerfect Transfection Reagent,
Qiagen). After 48 hours, total RNA was extracted from
cells and RT-PCR performed as described above.
Rhodamine uptake assay
Rhodamine uptake assay was performed to evaluate the
PGP transport function. Cells were treated as mentioned
above and incubated with PBS, Verapamil or Rhodamine
123. Rhodamine uptake was measured with FACS Canto
II Flow Cytometry System (Becton Dickinson, New
York, USA) and analyzed by FACS Diva 6.0 software as
described by Huet et al. [19].
Statistics
A one-way Anova test was carried out to reveal signifi-
cant differences in the mRNA expression. A value of
p ≤ 0.05 was defined as the level of significance. All sta-
tistical analyses were performed with SigmaStat 1.0 soft-
ware (Jandel Scientific, Sanrafael, CA, USA).
Results
Induction of multidrug resistance after chemotherapy
The effect of conventional chemotherapy on MDR protein
expression and function was analyzed by RT-PCR, Wes-
tern blot and Rhodamine uptake assay. PGP-, MRP1-,
MRP2- and MRP3-mRNA was detected by RT-PCR in
untreated HepG2 Chemotherapy induced multidrug resis-
tance in HepG2 cells. After treatment with gemcitabine, a
significant dose-dependent increase of ABC-transport pro-
tein mRNA expression was detectable compared to the
control group (p ≤ 0.05). After treatment of HepG2 cells
with gemcitabine 114 μg/ml the MRP2-, MRP3- and PGP-
mRNA levels were increased fourteen-, eleven- and four-
fold, respectively, compared to the control group (p ≤
0.05). Doxorubicin treatment lead to an enhanced mRNA
detection compared to controls (p ≤ 0.05). The levels of
MRP1- MRP2-, MRP3- and PGP-mRNA increased two-,
nine-, twenty- and seven-fold, respectively, after treatment
with doxorubicin 0.15 μg/ml (p ≤ 0.05) (Figure 1a). On a
protein level, a dose-dependent increase of MRP2 and
PGP expression was detected after Gemcitabine treatment
by Western blot analysis. Gemcitabine at a dose of 11.4
μg/ml increased the MRP2 protein levels by 43% and
Gemcitabine at a dose of 114 μg/ml by 76% compared to
the control group (p ≤ 0.05). Furthermore, PGP protein
levels increased by 20% after treatment with Gemcitabine
11.4 μg/ml and 139% after Gemcitabine at a dose of 114
μg/ml (p ≤ 0.05) (Figure 1b). A dose-dependent higher
PGP activity was detectable in the rhodamine uptake assay
after treatment with gemcitabine (Figure 1c).
Chemotherapy-induced effects on the tyrosine kinase
pathway
The effect of conventional chemotherapy on the mRNA
expression levels of various tyrosine kinases was analyzed
after induction of MDR. Chemotherapy induced the
expression of tyrosine kinase pathway associated mRNAs
in HepG2 cells. Gemcitabine increased mRNA levels of
R A F 1 ,E R K ,M A P K 1 4a n dE G F Rs i g n i f i c a n t l y( p≤ 0.05).
The expression of RAF1, ERK and EGFR increased two-
to three-fold of control values in a dose-dependent man-
ner. Doxorubicin lead to a dose-dependent two- to six-
fold increase of RAF1-, ERK- and MAPK14-mRNA
expression compared to controls (p ≤ 0.05) (Figure 2a).
Furthermore, treatment with gemcitabine or doxorubicin
lead to a dose-dependent increase of pERK protein expres-
sion by 3- and 2-folds, respectively, compared to the
untreated controls (Figure 2b).
Effects of EGF on multidrug resistance proteins
To investigate whether an activation of the tyrosine kinase
pathway would change the drug resistance phenotype, the
effects of EGF on drug resistant cells were evaluated with
RT-PCR and MTT assay. EGF increased the mRNA
expression of RAF1, MEK, ERK and MAPK14 significantly
in HepG2 cells (Figure 3a). Furthermore, EGF induced a
significant increase of MDR protein mRNA expression in
HepG2 cells. The mRNA levels of MRP2 and MRP3 were
three-fold higher in HepG2 cells after EGF treatment
compared to the controls (p ≤ 0.05) (Figure 3b). Survival
of resistant cells was increased after activation of the tyro-
sine kinase pathway in a time-dependent manner. Ninety-
six hours after EGF the survival of gemcitabine-treated
cells was 10-13% higher compared to cells treated with
gemcitabine alone (p ≤ 0.05) (Figure 3c).
Involvement of the EGFR in the regulation of multidrug
resistance
To evaluate whether the EGF receptor is involved in the
regulation of MDR, siRNA was used to inhibit its
Table 1 Primer Sequences
Protein Forward Primer Reverse Primer Length (bp)
RAF1 5’- AGACTGCTCACAGGGCCTTA-3’ 5’- CTGCAAATGGCTTCCTTCTC-3’ 79
MEK 5’- GGTGTTTATTGGGCCTCAGA-3’ 5’- ACCCGGAGCATCACAAATAG-3’ 78
ERK 5’- GACAAGGGCTCAGAGGACTG-3’ 5’- AGGACCAGGGGTCAAGAACT-3’ 71
MAPK14 5’- TTGGTCAGTGGGATGCATAA-3’ 5’- GGCTTGGCATCCTGTTAATG-3’ 140
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Figure 1 Chemotherapy induces multidrug resistance in HCC cells. Gemcitabine (11.4 μg/ml or 114 μg/ml) or Doxorubicin (0.15 μg/ml or
1.5 μg/ml) was added to HepG2 cells twice weekly and cultured in RPMI 1640 containing 10% FBS. A: mRNA expression of ATP-binding cassette
proteins was assessed by RT-PCR. Columns average of three independent experiments, bars SD. B: protein expression of ATP-binding cassette
proteins was assessed by Western blot. C: PGP transport function was assessed by Rhodamine uptake assay and analysed by FACS. *p ≤ 0.05
compared to the untreated control group.
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Figure 2 Chemotherapy induces the tyrosine kinase cascade mRNA expression in HCC cells. Gemcitabine (11.4 μg/ml or 114 μg/ml) or
Doxorubicin (0.15 μg/ml or 1.5 μg/ml) was added to HepG2 cells twice weekly and cultured in RPMI 1640 containing 10% FBS. A: Tyrosine
kinase mRNA expression was assessed by RT-PCR. Columns average of three independent experiments, bars SD. B: protein expression of tyrosine
kinases was assessed by Western blot. *p ≤ 0.05; **p ≤ 0.001 compared to the untreated control group.
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obtained (Figure 4a). After EGFR inhibition, the mRNA
levels of multidrug resistance proteins were significantly
decreased in resistant cells. Inhibition of EGFR in gem-
citabine-treated cells decreased PGP-, MRP1- and
MRP2-mRNA levels by 53%, 49% and 56%, respectively,
compared to cells with EGFR intact (p ≤ 0.05) (Figure
4b). Furthermore, the mRNA levels of both RAF1 and
MAPK14 were significantly lower after EGFR inhibition
and chemotherapy compared to resistant cells with
EGFR intact (p ≤ 0.05) (data not shown). Altogether, the
inhibition of the EGFR lowered the survival rate to 50%
compared to cells with EGFR intact (p ≤ 0.05). EGFR
inhibition in chemotherapy-treated resistant cells
decreased survival to 75% compared to resistant cells
with EGFR intact (p ≤ 0.001) (Figure 4c).
Effects of the specific EGFR inhibitor gefitinib on
multidrug resistance
To evaluate whether the addition of a clinically approved
EGFR inhibitor to conventional chemotherapy might
restore chemosensitivity, the effects of both, gemcitabine
and doxorubicin plus gefitinib were analyzed. Gefitinib
monotherapy did not change the EGFR protein expres-
sion but reduced the pERK expression (Figure 5a). While
the mRNA expression of PGP, MRP1, MRP2 or MRP3
did not change after gefitinib monotherapy, a simulta-
neous treatment of gefitinib and conventional che-
motherapy significantly restored the chemosensitivity in
HepG2 cells. The combination of gemcitabine plus gefiti-
nib reduced the MRP1-, MRP2- and MRP3-mRNA levels
two-, ten- and four-fold, respectively, compared to
monotherapy with gemcitabine (p ≤ 0.05). Doxorubicin
plus gefitinib decreased the PGP-, MRP1-, MRP2 and
MRP3-mRNA levels five-, three- nine- and nine-fold
compared to monotherapy with doxorubicin (p ≤ 0.05)
(Figure 5b).
Discussion
Hepatocellular carcinoma is a molecular complex tumor
with high intrinsic drug resistance [20]. New approaches
to overcome this resistance and offer patients tailored
treatment strategies are urgently required [21]. In this
study we investigated the ability of tyrosine kinase inhibi-
tion to restore chemosensitivity in HCC. We demon-
strate for the first time that EGFR inhibition sensitizes
HCC cells to conventional chemotherapy. Furthermore,
we provide evidence that EGFR-activated signal trans-
duction via the tyrosine kinase pathway is involved in the
development of MDR in HCC.
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Figure 3 EGF stimulated activation of the tyrosine kinase pathway increases the ABC-transport protein mRNA expression and cellular
proliferation of resistant HepG2 cells. Resistant HCC cells were cultured in RPMI 1640 and treated with EGF 500 ng/ml for 24 hours. A:
Tyrosine kinase mRNA expression was assessed by RT-PCR. Columns average of three independent experiments, bars SD. B: ABC-transport protein
mRNA expression was assessed by RT PCR. Columns average of three independent experiments, bars SD. C: Cellular viability was analyzed by
MTT assay. A minimum of three independent experiments was performed. *p ≤ 0.05 compared to the untreated control group.
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standard chemotherapy dramatically induces MDR in
both of the investigated HCC cells. Both gemcitabine
and doxorubicin treatment significantly increased the
ABC-transport protein expression and mRNA levels in a
time- and dose dependent manner. Additionally, cyto-
static treatment enhanced the PGP activity. Thus the
survival of drug resistant cells was significantly pro-
longed compared to chemo-sensitive cells. This is in
line with previous reports, demonstrating an up-regula-
tion of ABC-transport proteins in HepG2 cells as well
as in patients with HCC after chemotherapy [15,22].
The over-expression of drug-resistance proteins is an
independent prognostic factor for the impaired survival
of HCC patients and conventional chemotherapy has
shown only minor effectiveness, with low response rates
of 5-10% [4,8-10].
There is upcoming evidence of a potential link between
the tyrosine kinase pathway and ABC-transport proteins.
Previously, cisplatin-induced ERK activation was described
in human cervical carcinoma cells [23]. However, several
factors may be responsible for the modulation of the drug-
resistance phenotype and the regulatory mechanisms
involved have yet not been identified [5]. Up to now an
increased phosphorylation of ABC transporters by activa-
tion of the EGFR-RAS-MAPK cascade or modulation of
t h eM D Rt r a n s p o r t e rA T P a s ea c t i v i t yd u et ot y r o s i n e
kinase inhibition have been discussed [12,24]. In the pre-
sent study, we found that chemotherapeutic treatment
influenced the gene expression of tyrosine kinases. The
m R N Al e v e l so fR A F 1 ,E R K ,M A P K 1 4a n dt h eE G F R
increased in a dose-dependent manner after treatment
with gemcitabine or doxorubicin. Furthermore, che-
motherapy enhanced the activity of ERK and increased the
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Figure 4 EGFR inhibition by siRNA reduces the ABC-transport protein mRNA expression and cellular proliferation of HepG2 cells.A :
HepG2 cells were transfected with EGFR siRNA. EGFR mRNA expression was assessed by RT-PCR. Columns average of three independent
experiments, bars SD. EGFR protein expression analysed by Western blot. B: ABC-transport protein mRNA expression was determined by RT PCR
in HepG2 cells treated with EGFR siRNA. Columns average of three independent experiments, bars SD. *p ≤ 0.05; **p ≤ 0.001 compared to the
untreated control group. C: HepG2 cells were treated with EGFR siRNA, Gemcitabine 11, 4 μg/ml, Gemcitabine 11, 4 μg/ml plus EGFR siRNA,
Gemcitabine 114 μg/ml and Gemcitabine 114 μg/ml plus EGFR siRNA. Cellular viability was analyzed by MTT assay. A minimum of three
independent experiments was performed.
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dependent manner which is in line with a previous report
of Wang et al. [23].
To test the hypothesis of an interaction between the tyr-
osine kinase pathway and MDR we activated the EGFR-
RAS-MAPK cascade by EGF. A simultaneous increase of
MDR protein mRNA expression was found after EGF
treatment in both of he investigated HCC cell line, with
dramatically increased gene expression levels of PGP,
MRP2 and MRP3 mRNA. In line with this, PGP efflux
activity was enhanced and the cellular survival significantly
increased in a time-dependent manner. Simultaneously,
t h eg e n ee x p r e s s i o no fE G F - a c t i v a t e dt y r o s i n ek i n a s e s
increased. These observations are consistent with previous
reports on a potential influence of EGF on PGP and
MRP1 expression [16,25,26]. An EGF-stimulated activa-
tion of the EGFR and increased PGP protein expression
were described in colorectal cancer cells by Katayama
et al. [25]. Furthermore, enhanced MRP1 gene expression
and a high MRP1 promoter activity have been detected in
the presence of EGF in MCF-7 breast cancer cells [16].
Since our data indicate an involvement of the EGF-
mediated downstream activation of tyrosine kinases in
the regulation of ABC-transport proteins, we inhibited
the EGFR using siRNA. Consequentially, an increased
cytotoxicity of conventional chemotherapy and reduced
survival of resistant cells was detectable. The ABC-trans-
port protein gene expression was found to be
significantly lower after EGFR inhibition in these cells.
This supports the report of Garcia et al., who described a
decreased MRP1 expression after inhibition of the EGFR
in breast cancer cells for the first time [16]. In addition,
since the EGFR is over-expressed in several highly resis-
tant tumor entities and restoration of chemosensitivity
might have a significant therapeutic impact, we evaluated
the effects of gefitinib as a commercially available EGFR
inhibitor on the drug-resistance phenotype [27-29]. Gefi-
tinib is FDA approved for the treatment of advanced
non-small cell lung cancer and attaches to the ATP-bind-
ing site of the EGFR. This study clearly demonstrates
considerable chemosensitizing effects of combinative
treatment with gefitinib in resistant hepatocellular carci-
noma cells. The ABC-transport protein gene expression
levels dropped by up to ten-fold after addition of gefitinib
to gemcitabine or doxorubicin treatment. In line with
this, increased growth inhibitory activity was detected
and the cellular efflux function of PGP was reduced.
Recently, a dose-dependent reversal of drug resistance in
breast and lung carcinoma cell lines after simultaneous
treatment with clinically relevant doses of gefitinib has
been shown [30]. Furthermore, Gaikwad et al. detected
decreased PGP-mRNA levels after combinative treatment
with gefitinib and cisplatin in endometrial cancer cells
[31]. Nevertheless, synergistic effects of gefitinib and che-
motherapeutic agents have yet not been observed in clin-
ical trials [32,33].
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Figure 5 Gefitinib treatment restores the chemosensitivity in HepG2 cells. A: HepG2 cells were treated with Gefitinib 10 μg/ml and EGFR as
well as pERK protein expression was assessed by Western blot. B: HepG2 cells were treated with Gefitinib 10 μg/ml, Gemcitabine 114 μg/ml,
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†p ≤ 0.05;
††p ≤ 0.001
compared to the untreated control group; *p ≤ 0.05; **p ≤ 0.001 compared to monotherapy.
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In conclusion, the EGF-activated tyrosine kinase pathway
seems to be involved in the regulation of MDR in HCC.
The tyrosine kinase mRNA expression and phosphoryla-
tion is up-regulated in resistant HCC cells. Furthermore,
the gene expression and function of ABC-transport pro-
teins can be induced by EGFR activation. In contrast, the
inhibition of the EGFR restores the chemosensitivity of
drug-resistant HCC cells. In terms of a clinical perspec-
tive, the combination of EGFR inhibitor and selected
conventional chemotherapeutic agents may be a novel
strategy to improve the treatment efficacy of tailored
therapies in a variety of patients with highly resistant
tumors.
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